| Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044) |
|---|
| 08/21/2001 | US6277365 Ophthalmic composition including a cationic glycoside and an anionic therapeutic agent |
| 08/21/2001 | US6277363 Containing activated chlorine dioxide and disodium hydrogen phosphate, sodium dihydrogen phosphate, trisodium phosphate, or sodium monofluorophosphate |
| 08/21/2001 | US6277360 Pre-wetting solid particulate zinc pyridinethione with a low viscosity silicone fluid, dispersing the particulate zinc pyridinethione into a higher viscosity silicone fluid, emulsifying the dispersion so obtained |
| 08/21/2001 | US6277151 Using in vivo an amorphous, hydrated calcium phospate in an aqueous solution of a paste or putty consistency; having a biocompatibility with the cartilage-forming cell or precursor; hardening |
| 08/21/2001 | US6276917 Powder processing apparatus |
| 08/21/2001 | CA2319308C Pharmaceutical agents |
| 08/21/2001 | CA2294595C Inhibiting bone resorption |
| 08/21/2001 | CA2183960E Medicinal patches for percutaneous administration |
| 08/21/2001 | CA2180554C Preserved ophthalmic drug compositions containing polymeric quaternary ammonium compounds |
| 08/21/2001 | CA2176474C Viracidal, bactericidal and spermicidal vaginal suppository |
| 08/21/2001 | CA2100868C Derivatives of dicarboxylic acids having six to twelve carbon atoms and use of these derivatives and dicarboxylic acids alone in the preparation of pharmaceutical compositions forenteral and parenteral nutrition |
| 08/21/2001 | CA2052840C Lactoneotrehalose, and it's preparation and uses |
| 08/21/2001 | CA2018751C Stable freeze dried polyhematoporphyrin ether/ester composition |
| 08/16/2001 | WO2001059087A2 Compositions for transfecting nucleic acids and their use |
| 08/16/2001 | WO2001059067A2 A group of anti-cancer compounds with specific structure and their production method |
| 08/16/2001 | WO2001058961A1 Gels of hyaluronic acid cross-linked with bi-functional l-aminoacids or l-aminoesters or mixtures thereof |
| 08/16/2001 | WO2001058918A2 Oligonucleotides modulating the expression of enzymes involved in the synthesis of melanic pigments |
| 08/16/2001 | WO2001058910A2 Lipid-based drug delivery systems |
| 08/16/2001 | WO2001058892A1 Tyrosine derivatives with anti-leukotriene activity |
| 08/16/2001 | WO2001058885A1 Oxazolidinone thioamides with piperazine amide substituents |
| 08/16/2001 | WO2001058866A2 Ocular hypotensive lipids |
| 08/16/2001 | WO2001058849A1 SURFACE ACTIVE AGENTS DERIVED FROM 1-O-Nα-ACETYL-L-AMINOACYL ESTER 3-O-MONOACYL GLYCERIDES AND 1-O-Nα-ACETYL L-AMINOACYL ESTER 2,3-O-DIACYL GLYCERIDES TYPE AMINO ACIDS AND THE PREPARATION THEREOF |
| 08/16/2001 | WO2001058514A1 Drug delivery apparatus |
| 08/16/2001 | WO2001058511A1 Array and method for dosing a hormone regulating blood sugar in a patient |
| 08/16/2001 | WO2001058492A2 Carrier particles for drug delivery and process for preparation |
| 08/16/2001 | WO2001058474A2 Microencapsulation and sustained release of biologically active agent |
| 08/16/2001 | WO2001058472A2 Botulinum toxin pharmaceutical compositions |
| 08/16/2001 | WO2001058466A1 Biodegradable and biocompatible polymeric microspheres encapsulating salmonella enteritidisbacteria |
| 08/16/2001 | WO2001058464A1 Water dispersed ivermectin dosage form used for curing ecto- and endoparasitic diseases |
| 08/16/2001 | WO2001058458A1 Optically-active nanoparticles for use in therapeutic and diagnostic methods |
| 08/16/2001 | WO2001058455A1 Method to potentiate the therapeutic efficacy of taxane and derivatives thereof |
| 08/16/2001 | WO2001058452A1 Thermal ablation of tissue |
| 08/16/2001 | WO2001058451A1 Tamper-resistant oral opioid agonist formulations |
| 08/16/2001 | WO2001058449A1 Water dispersible formulation of paroxetine |
| 08/16/2001 | WO2001058447A1 Controlled-release compositions containing opioid agonist and antagonist |
| 08/16/2001 | WO2001058438A1 Ophthalmic use of alpha adrenergic blocking agents |
| 08/16/2001 | WO2001058435A1 Autonomic controlling agents |
| 08/16/2001 | WO2001058433A1 Timed pulsatile drug delivery systems |
| 08/16/2001 | WO2001058432A1 Apparatus for providing a red blood cell carrier |
| 08/16/2001 | WO2001058431A1 Method for loading a red blood cell with an agent |
| 08/16/2001 | WO2001058430A1 Bioadhesive composition |
| 08/16/2001 | WO2001058429A1 Acrylic enteric coating compositions |
| 08/16/2001 | WO2001058428A1 Method of preparing a sustained release composition |
| 08/16/2001 | WO2001058427A1 Particulate composition, method for producing said composition and use of the same |
| 08/16/2001 | WO2001058426A1 Sustained release composition comprising insuline like growth factor |
| 08/16/2001 | WO2001058425A2 Pharmaceutical composition for pulmonary delivery |
| 08/16/2001 | WO2001058424A1 Floating drug delivery composition |
| 08/16/2001 | WO2001058423A1 Novel use of pulmonary surfactant for the prophylaxis and treatment of chronic pulmonary diseases |
| 08/16/2001 | WO2001058408A2 Multi-purpose drug and heat therapy treatment system |
| 08/16/2001 | WO2001058238A2 Method and system for producing customized cosmetic and pharmaceutical formulations on demand |
| 08/16/2001 | WO2001051047A8 Use of fumaric acid derivatives for treating mitochondrial diseases |
| 08/16/2001 | WO2001024773B1 Liposome-entrapped dna oral vaccines |
| 08/16/2001 | WO2001022934A3 Delivery of small doses of ingestible treatments |
| 08/16/2001 | WO2001012201A8 Blood plasma replacement solution |
| 08/16/2001 | WO2001010415B1 A binder for pharmaceutical compositions |
| 08/16/2001 | WO2001010413A3 Periodic structures comprising lipids, polyelectrolytes, and structures-inducing soluble oligovalent linkers |
| 08/16/2001 | WO2001008688A3 Beta-carboline drug products |
| 08/16/2001 | WO2001007033A3 Neuroprotective pharmaceutical reparations comprising p-fluoroselegiline |
| 08/16/2001 | WO2000057866A3 Use of azalide antibiotics for the topical treatment or prevention of ocular infections |
| 08/16/2001 | WO2000056356B1 Induction of antigen-specific unresponsiveness by glioblastoma culture supernatants (gcs) |
| 08/16/2001 | WO2000047551A3 Inhibitors of aspartyl protease |
| 08/16/2001 | US20010014690 Substituted N-benzylindol-3-ylglyoxylic acid derivatives having antitumor action |
| 08/16/2001 | US20010014685 Injectable pharmaceutical composition for treatment and reversal of erectile dysfunction |
| 08/16/2001 | US20010014665 For oral administration to reduce nephrotoxicity and topically promote skin permeation in treatment of psoriasis |
| 08/16/2001 | US20010014475 Aggregate suitable for implantation comprising an aggregate of cells and biodegradable microcarrier particles; cell microcarrier aggregates are grown in mold shaped to conform to the geometry of the desired body part |
| 08/16/2001 | US20010014468 Magnetic polymer particles on the basis of polyvinyl alcohol, process for the production and use |
| 08/16/2001 | US20010014355 Differential immersion in a serum protein-containing solution |
| 08/16/2001 | US20010014354 Stability |
| 08/16/2001 | US20010014353 Directly compressible high load acetaminophen formulations |
| 08/16/2001 | US20010014352 Compressed tablet formulation |
| 08/16/2001 | US20010014351 Extraction from plant; adding glycerin to maintain solution; water and alcohol removal; encapsulation in vegetable gelatin or hydroxypropyl methylcellulose |
| 08/16/2001 | US20010014340 A tablet comprising; sugar alcohol or saccaride selected from mannitol and lactose, each having an average particle diameter of not more than 30 mu m, an active ingredient, and crosscarmellose sodium, crosspovidone etc. as disintegrant |
| 08/16/2001 | US20010014339 Forming a water in oil emulsion comprising a solution containing a water-soluble 2-piprazinone-1-acetic acid derivative and arganine as intergrin antagonist, a solvent, abiodegradable polymer, and fat and oil, removing the solvent |
| 08/16/2001 | US20010014338 Intermediate release nicotinic acid formulation having a dissolution curve similarity fit factor of about 79, and in in vitro dissolution profile in deionized water at about 100rpm; time release agents |
| 08/16/2001 | US20010014310 Applying to substrate an aqueous dispersion of solid particles comprising a crystalline polymer comprising units derived from a hydrophobic monomer; seed coatings to extend dormancy |
| 08/16/2001 | EP1123710A1 Freeze-dried hepatitis a attenuated live vaccine and its stabilizer |
| 08/16/2001 | EP1123700A1 Timed pulsatile drug delivery systems |
| 08/16/2001 | EP1123699A2 Tablet and process for making the same |
| 08/16/2001 | EP1123660A2 Encapsulation compositions |
| 08/16/2001 | EP1123396A2 Minimal promoters and uses thereof |
| 08/16/2001 | EP1123383A1 Surfactant protein d for the prevention and diagnosis of pulmonary emphysema |
| 08/16/2001 | EP1123342A1 Method for the production of spherical microparticles consisting totally or partly of at least one water-insoluble polyglucan containing branches and microparticles produced according to said method |
| 08/16/2001 | EP1123308A1 Single morphic forms of known peptide metalloproteinase inhibitors |
| 08/16/2001 | EP1123129A1 Systems and compounds for drug delivery to interstitial regions of the myocardium |
| 08/16/2001 | EP1123120A1 Medicinal aerosol formulation |
| 08/16/2001 | EP1123115A1 Treatment of trauma (ie graft rejection) with liposomes containing dna encoding for ctla4ig or for anti cd40l |
| 08/16/2001 | EP1123113A1 Ribozymes used as prodrugs |
| 08/16/2001 | EP1123106A1 Composition containing eugenol and polyphenols and use of such a composition for wound healing |
| 08/16/2001 | EP1123104A1 Inherently antimicrobial quaternary amine hydrogel wound dressings |
| 08/16/2001 | EP1123103A1 A process for producing an iron-dextran compound |
| 08/16/2001 | EP1123101A1 Fluticasone lotion having improved vasoconstrictor activity |
| 08/16/2001 | EP1123092A2 Fumaric acid microtablets |
| 08/16/2001 | EP1123089A1 Tablet for crunching with masked taste and instant release of active principle and method for making same |
| 08/16/2001 | EP1123088A1 Controlled-release pharmaceutical formulations containing a cgmp pde-5 inhibitor |
| 08/16/2001 | EP1123087A1 Oral pulsed dose drug delivery system |
| 08/16/2001 | EP1123085A1 O/w emulsion comprising an hydroxylated oil |
| 08/16/2001 | EP1123084A1 Use of testosterone esters and/or testosterone for producing bucally applicable bio-adhesive systems with time-released active ingredients |
| 08/16/2001 | EP1123082A1 Preparations for topical application of substances having antiandrogenic effect |
| 08/16/2001 | EP1123072A1 Anti-inflammatory and antimicrobial uses for bioactive glass compositions |
| 08/16/2001 | EP1123008A2 Preparation and use of solidified oils |